Physician profile
Thomas Cox
NPI 1770502387
$4,079.76
in general payments reported to CMS, 2019-2025
31 companies · $997 in 2025
The $997 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $699 · 2023: $919 · 2024: $1,049 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $635.77 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $432.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $389.08 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $372.44 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $227.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $208.50 | 2021-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Pfizer INC. | $207.16 | 2022-2025 | |
| Lundbeck LLC | $198.78 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $183.05 | 2021-2025 | Qelbree, Qelbree |
| Dexcom, INC. | $158.01 | 2021-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.40 | 2022-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $118.19 | 2023-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.20 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $91.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $61.93 | 2022-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $61.13 | 2021-2025 | |
| Astellas Pharma US INC | $49.74 | 2024-2025 | Veozah |
| Eisai INC. | $43.10 | 2021-2024 | |
| Axsome Therapeutics, INC. | $40.37 | 2025 | Auvelity |
| Becton, Dickinson and Company | $39.74 | 2023 | Bd Affirm Vpiii Microbial Identification Test |
| Vanda Pharmaceuticals INC. | $37.88 | 2025 | Fanapt |
| Phadia US INC. | $36.79 | 2023 | Immunocap |
| Cranial Technologies, INC | $34.83 | 2024-2025 | Doc Band |
| Bardy Diagnostics, INC. | $30.13 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.81 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $24.33 | 2021 | |
| Hologic Sales and Service, LLC | $23.79 | 2023 | Thinprep 2000 Processor, Aptima |
| E.R. Squibb & Sons, L.L.C. | $20.15 | 2025 | Cobenfy |
| Organon LLC | $20.13 | 2025 | Nexplanon |
| Kowa Pharmaceuticals America, INC. | $16.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.47 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.